CFDE Data Portal | Search FDPSP3

	Label	Description
	FDPSP3 Gene (Entity type)	ENSG00000258872 - farnesyl diphosphate synthase pseudogene 3
	GSE56010 adenosine 4 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE189035 inositol 2 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE185200 GSE185202 L-13 Ali-BL 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE115550 BRD4 inhibition 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE159678 hydroxychloroquine 6 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE178975 GSE178978 EGFR inhibition 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE217452 docetaxel 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE215461 topotecan 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE161302 GSE161304 enzalutamide LNCaP 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS

FDPSP3

ENSG00000258872 - farnesyl diphosphate synthase pseudogene 3

GSE56010 adenosine 4 v 1 human dn

A Gene Set from LINCS

GSE189035 inositol 2 v 7 human dn

A Gene Set from LINCS

GSE185200 GSE185202 L-13 Ali-BL 0 v 6 human up

A Gene Set from LINCS

GSE115550 BRD4 inhibition 2 v 1 human up

A Gene Set from LINCS

GSE159678 hydroxychloroquine 6 v 3 human up

A Gene Set from LINCS

GSE178975 GSE178978 EGFR inhibition 1 v 0 human up

A Gene Set from LINCS

GSE217452 docetaxel 2 v 0 human up

A Gene Set from LINCS

GSE215461 topotecan 0 v 1 human up

A Gene Set from LINCS

GSE161302 GSE161304 enzalutamide LNCaP 1 v 2 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.